L

Leap Therapeutics
D

LPTX

0.40460
USD
0.01
(1.81%)
مغلق
حجم التداول
1,305
الربح لكل سهم
-1
العائد الربحي
-
P/E
-0
حجم السوق
16,766,433
أصول ذات صلة
A
ARCT
-1.000
(-8.45%)
10.840 USD
BNTX
BNTX
-2.540
(-2.69%)
92.000 USD
C
CRNX
0.370
(1.20%)
31.290 USD
MRNA
MRNA
-1.520
(-5.95%)
24.030 USD
T
TBPH
-0.49000
(-5.51%)
8.41000 USD
V
VERU
-0.00830
(-1.62%)
0.50320 USD
المزيد
الأخبار المقالات

العنوان: Leap Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patientswith colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.